Skip to main content
SpringerLink
Log in

Does the Addition of Luteinizing Hormone in Ovarian Stimulation Protocols Improve the Outcome?

  • Current Opinion
  • Published:
Treatments in Endocrinology

Abstract

Ovarian stimulation is an integral part of assisted reproductive technologies (ART). Under physiologic conditions, both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity is necessary to guarantee follicle growth and maturation. This can be shown in patients with hypogonadotrophic hypogonadism, who have no endogenous FSH or LH activity. The use of FSH alone in these patients does not result in sufficient follicle growth and oocyte quality. Approximately 75IU of LH activity per day is necessary to guarantee optimal success. The use of gonadotropin-releasing hormone (GnRH) agonists in normogonadotrophic patients may result in suppression of LH levels below a certain threshold, resulting in suboptimal outcomes. The question under discussion in this article is the threshold level of LH below which exogenous LH activity should be added to provide optimal ovarian response. Different studies indicate that the endogenous LH level should be 0.5–1.5IU in long-term protocol situations.

Patients treated in ultra-long GnRH agonist protocols, as well as older patients, patients with a low response to gonadotropin treatment, and patients treated with a GnRH antagonist protocol may benefit from exogenous LH activity. There are three ways of adding LH activity in ovarian stimulation cycles. Nowadays, lutropin alfa (recombinant LH) may be the optimal choice since it has no chorionic gonadotropin activity and allows individual dosage titration. Every menotropin preparation currently on the market contains some chorionic gonadotropin activity. However, more data are necessary before evidence-based recommendations regarding LH supplementation in ovarian stimulation protocols can be given.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. The use of tradenames is for product identification purposes only and does not imply endorsement

References

  1. Gougeon A. Dynamics of follicular growth in the human: a model from preliminary results. Hum Reprod 1986; 1: 81–7

    PubMed  CAS  Google Scholar 

  2. Oktay K, Newton H, Mullan J, et al. Development of human primordial follicles to antral stages in SCID/hpg mice stimulated with follicle stimulating hormone. Hum Reprod 1998; 13: 1133–8

    Article  PubMed  CAS  Google Scholar 

  3. Ryan KJ, Petro Z. Steroid biosynthesis by human ovarian granulosa and thecal cells. J Clin Endocrinol Metab 1966; 26: 46–52

    Article  PubMed  CAS  Google Scholar 

  4. Filicori M, Cognigni GE, Pocognoli P, et al. Modulation of folliculogenesis and steroidogenesis in women by graded menotrophin administration. Hum Reprod 2002; 17: 2009–15

    Article  PubMed  CAS  Google Scholar 

  5. Filicori M, Cognigni GE, Tabarelli C, et al. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab 2002; 87: 1156–61

    Article  PubMed  CAS  Google Scholar 

  6. Adams J, Poison DW, Abdulwahid N, et al. Multifollicular ovaries: clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 1985; II: 1375–9

    Article  Google Scholar 

  7. Homburg R, Jacobs HS. Etiology of miscarriage in polycystic ovary syndrome. Fertil Steril 1989; 51: 196–8

    PubMed  CAS  Google Scholar 

  8. Homburg R, Levy T, Berkovitz D, et al. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome. Fertil Steril 1993; 59: 527–31

    PubMed  CAS  Google Scholar 

  9. Ludwig M, Finas DF, Al-Hasani S, et al. Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum Reprod 1999; 14: 354–8

    Article  PubMed  CAS  Google Scholar 

  10. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524–9

    Article  PubMed  CAS  Google Scholar 

  11. Stadtmauer LA, Wong BC, Oehninger S. Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome: beyond ovulation induction. Hum Reprod 2002; 17: 3016–26

    Article  PubMed  CAS  Google Scholar 

  12. Glueck CJ, Wang P, Goldenberg N, et al. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17: 2858–64

    Article  PubMed  CAS  Google Scholar 

  13. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75: 46–52

    Article  PubMed  CAS  Google Scholar 

  14. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod 1994; 9: 188–91

    PubMed  CAS  Google Scholar 

  15. Balasch J, Miro F, Burzaco I, et al. The role of luteinizing hormone in human follicle development and oocyte fertility: evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone. Hum Reprod 1995; 10: 1678–83

    PubMed  CAS  Google Scholar 

  16. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. The European Recombinant Human LH Study Group. J Clin Endocrinol Metab 1998; 83: 1507–14

    Article  Google Scholar 

  17. Fleming R, Chung CC, Yates RW, et al. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity. Hum Reprod 1996; 11: 1854–8

    Article  PubMed  CAS  Google Scholar 

  18. Daya S, Gunby J. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction. Hum Reprod 1999; 14: 2207–15

    Article  PubMed  CAS  Google Scholar 

  19. Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril 2002; 77: 711–4

    Article  PubMed  Google Scholar 

  20. Chappel SC, Howies C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991; 6: 1206–12

    PubMed  CAS  Google Scholar 

  21. Fleming R, Lloyd F, Herbert M, et al. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. Hum Reprod 1998; 13: 1788–92

    Article  PubMed  CAS  Google Scholar 

  22. Fleming R, Rehka P, Deshpande N, et al. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH. Hum Reprod 2000; 15: 1440–5

    Article  PubMed  CAS  Google Scholar 

  23. Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000; 15: 1003–8

    Article  PubMed  CAS  Google Scholar 

  24. Esposito MA, Barnhart KT, Coutifaris C, et al. Role of periovulatory luteinizing hormone concentrations during assisted reproductive technology cycles stimulated exclusively with recombinant follicle-stimulating hormone. Fertil Steril 2001; 75: 519–24

    Article  PubMed  CAS  Google Scholar 

  25. Fanchin R, Schönauer L, Righini C, et al. Beneficial effects of residual LH levels after GnRH agonist on ovarian response to r-FSH, embryo quality, and IVF-ET outcome [abstract]. Fertil Steril 2001; 76Suppl. 1: S91

    Article  Google Scholar 

  26. Balasch J, Vidal E, Penarrubia J, et al. Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. Hum Reprod 2001; 16: 1636–43

    Article  PubMed  CAS  Google Scholar 

  27. Humaidan P, Bungum L, Bungum M, et al. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod 2002; 17: 2016–21

    Article  PubMed  CAS  Google Scholar 

  28. Balasch J, Creus M, Fabregues F, et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction. J Assist Reprod Genet 2001; 18: 250–6

    Article  PubMed  CAS  Google Scholar 

  29. Filicori M. The role of luteinizing hormone in folliculogenesis and ovulation induction. Fertil Steril 1999; 71: 405–14

    Article  PubMed  CAS  Google Scholar 

  30. Erickson GF, Magoffin DA, Dyer CA, et al. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 1985; 6: 371–99

    Article  PubMed  CAS  Google Scholar 

  31. Cortvrindt R, Hu Y, Smitz J. Recombinant luteinizing hormone as a survival and differentiation factor increases oocyte maturation in recombinant follicle stimulating hormone-supplemented mouse preantral follicle culture. Hum Reprod 1998; 13: 1292–302

    Article  PubMed  CAS  Google Scholar 

  32. Loumaye E, Engrand P, Howies CM, et al. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997; 67: 889–99

    Article  PubMed  CAS  Google Scholar 

  33. Lisi F, Rinaldi L, Fishel S, et al. Use of recombinant LH in a group of unselected IVF patients. Reprod Biomed Online 2002; 5: 104–8

    Article  PubMed  CAS  Google Scholar 

  34. De Placido G, Mollo A, Alviggi C, et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod 2001; 16: 1875–9

    Article  PubMed  Google Scholar 

  35. Karande VC. Managing and predicting low response to standard in vitro fertilization therapy: a review of the options. Treat Endocrinol 2003; 2(4): 257–72

    Article  PubMed  Google Scholar 

  36. Ludwig M, Strik D, al Hasani S, et al. No transfer in a planned ICSI cycle: we cannot overcome some basic rules of human reproduction. Eur J Obstet Gynecol Reprod Biol 1999; 87: 3–11

    Article  PubMed  CAS  Google Scholar 

  37. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for ART compared to the long protocol: a meta-analysis. Arch Gynecol Obstet 2001; 265: 175–82

    Article  PubMed  CAS  Google Scholar 

  38. Ludwig M, Katalinic A, Banz C, et al. Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002; 17: 2842–5

    Article  PubMed  CAS  Google Scholar 

  39. de Jong D, Macklon NS, Eijkemans MJ, et al. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertil Steril 2001; 75: 688–93

    Article  PubMed  Google Scholar 

  40. Filicori M, Cognigni GE, Taraborrelli S, et al. Low-dose human chorionic gonadotropin therapy can improve sensitivity to exogenous follicle-stimulating hormone in patients with secondary amenorrhea. Fertil Steril 1999; 72: 1118–20

    Article  PubMed  CAS  Google Scholar 

  41. Filicori M, Cognigni GE, Taraborrelli S, et al. Luteinizing hormone activity supplementation enhances follicle-stimulating hormone efficacy and improves ovulation induction outcome. J Clin Endocrinol Metab 1999; 84: 2659–63

    Article  PubMed  CAS  Google Scholar 

  42. Giudice E, Crisci C, Altarocca V, et al. Characterization of a partially purified human menopausal gonadotropin preparation. J Clin Res 2001; 4: 27–34

    Google Scholar 

  43. Rodgers M, McLoughlin J, Peers N, et al. Accumulation of human chorionic gonadotrophin in the serum of patients during in-vitro fertilization treatment cycles with Pergonal. Hum Reprod 1994; 9: 638–42

    PubMed  CAS  Google Scholar 

  44. Stokman PG, De Leeuw R, van den Wijngaard HA, et al. Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertil Steril 1993; 60: 175–8

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre of Reproductive Medicine and Gynecologic Endocrinology, Endokrinologikum Hamburg, Lornsenstraβe 4-6, Hamburg, 22767, Germany

    Michael Ludwig

Authors
  1. Michael Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Ludwig.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ludwig, M. Does the Addition of Luteinizing Hormone in Ovarian Stimulation Protocols Improve the Outcome?. Mol Diag Ther 2, 305–313 (2003). https://doi.org/10.2165/00024677-200302050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200302050-00002

Keywords

Search

Navigation